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TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS 1
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have established
that ambulatory treatment of pulmonary tuberculosis with a standard daily regimen of
isoniazid plus PAS for one year yields satisfactory results. However, this regimen may
be unsuitable for large-scale use in many developing countries, because PAS is expensive,
bulky and unpleasant to take, and has poor keeping qualities, especially in tropical countries.
It might be possible to overcome these disadvantages, by substituting for the PAS a drug
which is equally effective but less expensive and more acceptable, or by reducing the daily
dosage of PAS and the period for which it is prescribed.
This paper presents the results over a II-month period of a controlled comparison of
(a) the standard regimen of isoniazid (average 4.5 mg/kg body-weight) plus sodium PAS
(average 0.22 g/kg), daily in two divided doses ; (b) a regimen of isoniazid (average
6.9 mg/kg) plus thioacetazone (average 3.4 mg/kg), daily in one dose ; and (c) a 2-phase
regimen of isoniazid (average 5.5 mg/kg) plus sodium PAS (average 0.17 g/kg), daily
in one dose for 6 months, followed by isoniazid alone (average 6.8 mg/kg), daily in one
dose for the second 6 months.The regimen of isoniazid plus thioacetazone was found to be
therapeutically as effective as the standard regimen of isoniazid plus PAS ; however, it was
associated with a higher incidence of minor side-effects, and three cases of exfoliative
dermatitis. The 2-phase regimen of isoniazid plus PAS followed by isoniazid alone was
less effective.
These findings are encouraging for the large-scale use in developing countries of the
relatively inexpensive regimen of isoniazid plus thioacetazone ; however, any such step
should be preceded by carefully planned studies to investigate, under local conditions, the
toxicity and the efficacy of the regimen.
* Thioacetazone is the recommended international non-
proprietary name (see World Health Organization, 1962)
for 4'-formylacetanilide thiosemicarbazone (thiacetazone,
Tb I-698).
1 The Centre is under the joint auspices of the Indian
Council of Medical Research (ICMR), the Madras State
Government, the World Health Organization (WHO) and
the Medical Research Council of Great Britain (BMRC).
The members of the scientific staff of the Centre with major
responsibility for the work reported here are: Dr Hugh Stott
(WHO), Senior Medical Officer; Dr J. J. Y. Dawson (WHO),
Dr C. V. Ramakrishnan (ICMR) and Dr S. Velu (Madras
Government), Medical Officers; Dr S. Devadatta (ICMR),
Assistant Medical Officer; Dr S. R. Kamat (ICMR), Senior
Research Officer; Dr J. B. Selkon (WHO), succeeded by
Dr E. M. Mackay-Scollay (WHO), and Dr S. P. Tripathy
(ICMR), Bacteriologists; Dr P. R. J. Gangadharam (ICMR),
Dr K. V. Nageswara Rao (ICMR) and Mr C. Narayanan
Nair (ICMR), Assistant Bacteriologists; Dr D. V. Krishna-
murthy (ICMR), Biochemist; Mr C. V. Jacob (ICMR),
Miss S. Joseph (ICMR), Mrs S. Subbammal (ICMR) and
Mr P. Venkataraman (ICMR), Laboratory Research
Assistants; Mr P. Hinchliffe (WHO), Laboratory Technician;
Dr S. Radhakrishna (Madras Government), Senior Statis-
tician; Mr K. Ramachandran (ICMR) and Mr P. R. Soma-
sundaram (ICMR), Statisticians; and Mr B. Janardhanam
(ICMR) and Mr A. S. L. Narayana (ICMR), Senior Assistant
Statisticians.
The research of the Centre is guided by a Project Com-
mittee consisting of three ICMR representatives (Dr P. V.
Benjamin, Convener, succeeded in July 1962 by Dr N. L.
Bordia, Dr J. Frimodt-Møller and Dr K. S. Sanjivi), the
Director of the ICMR (Dr C. G. Pandit, succeeded by
Col. B. L. Taneja in August 1964), the Director of Medical
Services, Madras State (Dr A. B. Marikar), a WHO repre-
sentative (appointed for each meeting), a BMRC repre-
sentative (appointed for each meeting), the Director of the
Centre (Dr N. K. Menon) and the Senior Medical Officer
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I. INTRODUCTION
In many developing countries, the resources
available for the control of tuberculosis are very
limited (Canetti, 1962; Fox, 1964). Therefore, the
development of inexpensive but effective, acceptable
and non-toxic drug regimens for mass treatment of
patients is of great importance. Chemotherapy with
a daily regimen of isoniazid plus p-aminosalicylic
acid (PAS) is too expensive for large-scale use in
many countries; furthermore, PAS is bulky and
unpleasant to take, and its keeping properties,
especially in tropical countries, are not good. Iso-
niazid alone is inexpensive and small in bulk, but is
not sufficiently effective even in its optimal thera-
peutic dosage of 8-9 mg/kg given in one daily dose
(Tuberculosis Chemotherapy Centre, Madras, 1960,
1963b).
Preliminary results in 1961 from East Africa
suggested that an inexpensive regimen of 300 mg of
isoniazid plus 150 mg of thioacetazone1 in a single
daily dose was therapeutically as effective and of
the same order of toxicity as isoniazid plus PAS
(J. Heffeman, personal communication ; subsequently
published as East African/British Medical Research
Council Second Thiacetazone Investigation, 1963).
It was therefore decided to compare the value of this
regimen in India with a standard daily regimen of
200 mg of isoniazid plus 10 g of sodium PAS for
one year.
Since the latter regimen is expensive, largely
owing to the PAS, a reduction in the daily dosage of
sodium PAS from 10 g in two divided doses to 6 g
in one dose was also investigated. It was decided
to give the total daily dosage of 6 g in one rather
than two doses for the following reasons. First,
Bridge & Carr (1958) had reported that, in combi-
nation with isoniazid, 7 g of sodium or calcium PAS
in  single daily dose was as effective as, and better
tolerated than, 9-12 g given in three or four doses a
day. Secondly, Karlson & Carr (1958) had demon-
strated that a single daily dose of PAS was as effective
in guinea-pigs as the same dosage or twice the dosage
given daily in two doses. Finally, there is evidence
that a single high daily dose of PAS results in higher
blood concentrations of free PAS than repeated
small doses, because a larger margin of free PAS
remains after acetylation (Lehmann, 1959; Wagner,
Fajkosova & Simane, 1960). In order to reduce the
cost of the regimen further and since, when the study
was planned, there was some evidence (subsequently
p blished as Great Britain, Medical Research
Council, 1962) that it is the early phase of chemo-
therapy that is crucial to the outcome of treatment,
the reduced dosage of 6 g of sodium PAS was given
with isoniazid for the first 6 months only, and was
followed by isoniazid alone for the second 6 months
of treatment.
II. PLAN AND CONDUCT OF THE STUDY
The great majority of patients came from theno antituberculosis chemotherapy or had received
poorest sections of the population of Madras Cityit for not more than two weeks, and were judged
and were admitted on the same criteria as in previous
investigations (Tuberculosis Chemotherapy Centre,
to be co-operative, that is, prepared to have at least
Madras, 1959, 1960, 1964); in particular, they wereone year of domiciliary chemotherapy and willing
aged 12 years or more, had bacteriologically con-to attend the Centre subsequently for follow-up
firmed pulmonary tuberculosis, had either receivedinv stigations.
[Continued from previous page]
of the Centre (Dr Hugh Stott). The joint secretaries haveat the Tuberculosis Chemotherapy Centre, Madras, and the
been Mr. D Chakravarti, and Mr B. S. Verma succeeded byreport prepared by Dr H. Stott and Dr S. Radhakrishna in
Mr V. S. Talwar in April 1962. The BMRC, acting throughcollaboration with the medical and statistical staff of the
its Tuberculosis and Chest Diseases Research Unit, isCentre.
responsible for advising WHO on the research in accordanceThe great majority of the patients in the present study
with plans prepared by the Project Committee. Close contactwere referred to the Centre from the Government Chest
is maintained between the Centre and Dr Wallace FoxInstitute, Madras (Director: Dr M. A. Hamid), and the
(BMRC Tuberculosis and Chest Diseases Research Unit),Corporation Tuberculosis Clinic, Pulianthope (Medical
Dr Ian Sutherland (BMRC Statistical Research Unit) andOfficer in Charge: Dr V. S. Selvapathy)
Dr D. A. Mitchison (BMRC Unit for Research on Drug
Sensitivity in Tuberculosis). The analyses were undertaken1 See footnote * on preceding page.
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TABLE 1
MEAN DOSAGE AND RANGE OF ISONIAZID, SODIUM PAS AND THIOACETAZONE
IN THE THREE SERIES
Isoniazid Sodium PAS Thioacetazone
Regimen
Mean Range Mean Range Meandosage    dosage dosage Range
At start of
treatment
PH
TH
4.5 3.7-6.6 0.22 0.19-0.33              – –
6.9 4.6-8.0            – – 3.4 2.3-4.0
At 6 months
P6H/H
P6H/H
5.5 4.0-9.2 0.17 0.12-0.28        – –
6.8 6.2-7.7        – –
PRETREATMENT INVESTIGATIONS CHEMOTHERAPEUTIC REGIMENS
The pretreatment investigations included among
others :
1. A full clinical examination, assessment of the
general clinical condition, the weight (lb), exami-
nation of the urine for albumin, sugar, bilirubin
(Sobotka, Luisada-Opper & Reiner, 1953) and
spectroscopic examination for urobilin (Harrison,
1957).
Three chemotherapeutic regimens were studied;
the details of chemotherapy and the dosages for
patients weighing 100 lb (45.4 kg) were as follows:
PH. Isoniazid 200 mg plus sodium PAS 10 g,
daily for one year; the two drugs were prescribed
together in cachets, four to be taken in the morning
and four in the evening.
2. A full-plate postero-anterior radiograph of the
chest.
3. The examination by direct smear and culture
of a minimum of four sputum specimens; two were
produced overnight in the home (collection speci-
mens) and two were expectorated under supervision
at the Centre (supervised spot specimens).
4. Tests of sensitivity to isoniazid, PAS and thio-
acetazone on two cultures.
TH. Isoniazid 300 mg plus thioacetazone 150 mg,
daily for one year; the two drugs were prescribed
together as a single morning dose of six tablets.
P6H/H. Isoniazid 200 mg plus sodium PAS 6 g,
daily for the first 6 months; the two drugs were
prescribed together as a single morning dose of
four cachets. For the second 6 months, isoniazid
alone in a dosage of 300 mg daily was prescribed as
a single morning dose of six tablets.
5. The estimation of the haemoglobin, packed cell
volume (PCV) and a total and differential leucocyte
count.
6. The determination of the whole blood L -
aspartate: 2-oxoglutarate aminotransferase 1 (gluta-
mic-oxaloacetic transaminase, GOT) level by the
method of Yatzidis (1960) and of the serum GOT
level by the procedure described by the Sigma
Chemical Company, St. Louis, MO. USA (1961),
for patients in two of the series, TH and P6H/H
(see below).
The dosages of drugs were related to the patient’s
weight (see Appendix Table A) with the exception
of the P6H/H regimen in the first 6 months, when
both isoniazid and PAS were prescribed in the
uniform dosage mentioned above. Table 1 shows
the mean dosages and the ranges at the start of treat-
ment for each of the three treatment series and, in
addition, at six months for the P6H/H series.
ALLOCATION OF CHEMOTHERAPY
‘Terminology recommended by the Commission on
Enzymes of the International Union of Biochemistry (1961).
On the basis of the smear result of the first collec-
tion specimen of sputum, which was 3-plus, 2-plus,
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l-plus or negative, the patients were classified into
four categories. Treatment was allocated by the
statisticians from four series of sealed envelopes
(one for each category), based on random sampling
numbers. Nobody had prior knowledge of the
chemotherapy which any individual patient would
receive. The first allocation was made on 15 January
1962 and the last on 21 March 1963.
GENERAL MANAGEMENT
The patients were treated at home with super-
vision of their progress at the Centre; they attended
the Centre once a week to collect drugs, which were
to be taken at home. Two visits, at approximately
fortnightly intervals, were usually made by a health
visitor to the patient’s home every month. At one
visit, which was unannounced, the stock of cachets
or tablets was counted and a specimen of urine was
collected, to check whether the patient was taking
the drugs; the other visit, towards the end of each
month of treatment, was to deliver a sputum speci-
men bottle.
If a patient was too ill to attend the Centre at the
start of treatment, the drugs were delivered to the
home, weekly. This was done for only a very few
patients, and as soon as they improved sufficiently,
which was usually by the end of one month of
treatment, they were put on to the ordinary routine
of clinic and home visits.
ASSESSMENTS OF PROGRESS
Assessments made at monthly intervals after the
start of chemotherapy included (1) the weight,
(2) a postero-anterior chest radiograph, (3) the ex-
amination of two collection specimens and one
supervised spot specimen of sputum by smear and
cultur , and (4) tests of sensitivity to the allocated
drugs on one positive culture. (However, in the case
f PH and P6H/H patients, tests of sensitivity to
PAS were set up only on one 6-month culture and
one 12-month culture.)
As anaemia, agranulocytosis and hepatitis may
occur as toxic manifestations of thioacetazone
(Hinshaw & McDermott, 1950; Bunn, 1950), the
haemoglobin, PCV, total and differential leucocyte
counts, and serum GOT estimations were performed
at 3, 9 and 12 months in the TH series, and also in
the P6H/H series as a control. As a further control,
the haematological examinations were undertaken
at 12 months in the PH series. Whole blood GOT
estimations were undertaken for pyridoxine de-
ficiency (Krishnamurthy et al., in preparation) at 3,
9 and 12 months in the TH series, and in the P6H/H
series as a control, as a measure of isoniazid toxicity.
Unless they were urgently required for the manage-
ment of the patients, the results of these tests were
withheld from the clinicians in order to avoid possible
bias in the assessment and interpretation of clinical
signs and symptoms. A specimen of urine was
examined spectroscopically for urobilin each week
for every patient.
In order to check the self-administration of drugs,
a urine specimen was obtained at each weekly visit
of the patient to the Centre and at the unannounced
monthly visit to the home by the health visitor,
The specimens from patients in the PH and P6 /H
series were tested for the presence of PAS by the
ferric chloride test (Simpson, 1956), and those from
patients in the TH and P6H/H series for isoniazid
by t e combined naphthoquinone-mercuric chloride
test (Gangadharam et al., 1958).
III. BACTERIOLOGICAL PROCEDURES
SMEARS, CULTURES AND SENSITIVITY TESTS after treatment with 4% NaOH for 20 minutes, on
The methods used for examining sputum speci-
Löwenstein-Jensen medium which did not contain
mens are similar to those described previouslypotato starch (Jensen, 1955). The cultures were
(Tuberculosis Chemotherapy Centre, Madras, 1959).examined weekly for 8-9 weeks and were reported
In brief, sputum smears were examined by fluo-as negative if no growth was present by that time.
rescence microscopy (Hoist, Mitchison & Radha-Sensitivity tests were set up on Löwenstein-
krishna, 1959) and were classified as 3-plus, 2-plus,Jensen medium slopes containing the drug con-
l-plus or negative. Sputum specimens were cultured,cent ations (expressed as the amounts added before
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inspissation) set out below, as well as on a drug-Isoniazid
free slope as control. Pretreatment :
Drug
Isoniazid
Drug concentration (µg/ml)
Test strain H37Rv
0.2, 1, 5, 50 0.025, 0.05, 0.1, 0.2, 1
Sodium PAS
dihydrate 0.5, 1, 2, 4, 8, 16    0.125, 0.25, 0.5, 1, 2
Thioacetazone0.25, 0.5, 1, 2,0.25, 0.5, 1, 2, 4, 8,
4, 8, 16, 32 16, 32
(a) growth on 1 µg/ml on one culture, irrespective
of the result on the other culture; or
(b) growth on 0.2 µg/ml but not on 1 µg/ml,
followed by growth on 0.2 µg/ml in a repeat test
on the same culture, irrespective of the result on the
other culture; or
A standard suspension of the culture (inoculum
of approximately 0.01 mg (moist weight) of bacilli
on each slope) was used in the isoniazid sensitivity
test, a 1 : 10 dilution of this suspension for the
PAS test as recommended by Selkon et al. (1960),
and both the standard suspension and a 1:20
dilution for the thioacetazone test. (In the case of the
thioacetazone test, the drug was dissolved in tri-
ethylene glycol before incorporation in the medium,
the final concentration of triethylene glycol being
0.5% in all slopes; also, an additional drug-free
slope containing 0.5 % triethylene glycol was set up.)
The standard sensitive strain, H37Rv, was set up
with every batch of tests. The results of all the tests
were read at the end of four weeks of incubation
at 37°C.
(c) growth on 0.2 µg/ml but not on 1 µg/ml on
both cultures, irrespective of the results of repeat
tests.
During treatment : growth on 0.2 µg/ml.
PAS
Pretreatment and during treatment. A culture was
defined as PAS-resistant if it yielded a resistance
ratio (that is, minimal inhibitory concentration
(MIC) of the test strain expressed as a proportion
of the MIC of the standard sensitive strain, H37Rv)
of 8 or more, or 4 followed by 4 or more in a repeat
test.
Thioacetazone
On the available evidence, it has not been possible
to define thioacetazone resistance (see page 495).
RATE OF INACTIVATION OF ISONIAZID
DEFINITIONS OF DRUG RESISTANCE
In the definitions of resistance given below,
“ growth ” has been defined as 20 colonies or more:
On admission to treatment, the rate of inactivation
of isoniazid was determined for each patient by the
microbiological assay method of Gangadharam et al.
(1961).
IV. PATIENTS ADMITTED TO TREATMENT
In all, 240 patients were admitted to treatment,chemotherapy, apart from 6 patients (2 PH, 3 TH,
79 to the PH, 80 to the TH and 81 to the P6H/H 1 P6H/H) who had had up to two weeks of chemo-
series. Of these, 17 (6 PH, 2 TH, 9 P6H/H) were therapy.
subsequently found to have been excreting isoniazid-No attempt has been made to exclude from the
resistant organisms on admission, 1 (PH) hadanalysis patients with PAS- or thioacetazone-resis-
anomalous pretreatment sensitivity results and 2tant strains at the start of treatment because of the
(1 TH, 1 P6H/H) had had anonymous mycobacterialdiff culty of identifying such patients with certainty.
infections. These 20 patients have been excluded
from the main analysis and are considered in section
IX. There remain 220 patients (72 PH, 77 TH,
COMPARISON BETWEEN THE THREE SERIES
71 P6H/H) in the main analysis who, on admission
ON ADMISSION TO TREATMENT
to the study, (a) had organisms sensitive to isoniazidOf the 72 patients in the PH series, 71% were
and (b) had had, so far as is known, no previousmale , as compared with 68 % of 77 in the TH series
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and 58 % of 71 in the P6H/H series. More than half
the patients were between the ages of 15 and 34—
namely, 57 % of the PH, 55 % of the TH and 54 %
of the P6H/H series. The weight distributions of
the patients were similar (Table 2); the mean weights
were 84, 86 and 82 lb, respectively.
TABLE 2
CONDITION ON ADMISSION TO TREATMENT
Condition on admission
to treatment
Weight (lb a):
100 or more
80-99
Under 80
Extent of cavitation:
Nil
Slight
Moderate
Extensive
PH
patients
No. %
TH
patients
No. %
P6H/H
patients
No. %
9 12 12 16 11 15
38 53 36 47 32 45
25 35 29 38 26 39
26 36 33  43 24 34
14 19 12 16 15 21
30 42 32 42 29 41
2 3 0 0 3 4
Total extent of disease:
Slight
Limited
Moderate
Extensive
Gross
1 1 2 3 3 4
36 50 36 47 36 51
26 36 30 39 23 32
7 10 8 10 6 8
2 3 1 1 3 4
Number of long zones
involved in disease:
1, 2 or 3
4, 5 or 6
16 22 23 30 23 32
56 78 64 70 46 68
Bacterial content of
sputum : b
Direct smear negative
Direct smear positive:
1-plus (scanty)
2-plus (moderate)
3-plus (heavy)
7 10
23 32
34 47
8 11
Total patients 72 100
a 1 lb = 0.45 kg.
b First or only collection specimen.
10 13
24 31
35 45
8 10
77 100
7 10
26 37
30 42
8 11
71 100
The extent of cavitation, the total extent of the
ra iographic lesion and the number of lung zones
involved in disease were assessed, as described
previously (Tuberculosis Chemotherapy Centre,
Madras, 1960), from a single full-plate radiograph
by an independent assessor (Dr Raj Narain), who
was unaware of the treatment series or any other
detail of any patient (Table 2). Cavitation was
present in 64 % of the PH, 57 % of the TH and 66 %
of the P6H/H patients, being extensive or moderate
in 44%, 42% and 45 %, respectively. Gross or
extensive disease was present in 13% of the PH,
12 % of the TH and 13 % of the P6H/H patients, and
4 or more lung zones were involved in disease in
78 %, 70 % and 68 %, respective1y.1
Considering the direct smear result of the first or
only collection specimen of sputum (Table 2), 58%
of the PH, 56% of the TH and 54% of the P6H/H
patients had a 3-plus or 2-plus result; only 10%,
13 % and 10%, respectively, had a negative result.
It may be concluded that the three series of
patients were similar on admission to treatment.
PLAN OF THE REST OF THE REPORT
The next section (section V) compares the response
to treatment of patients during the 12-month period
in the three series. Section VI studies the prognostic
importance of various characteristics at the start of
treatment. Section VII deals with drug toxicity and
other complications of treatment, section VIII with
the acceptability of the regimens and the co-operation
of patients and section IX with the 20 patients not
included in the main analysis. This presentation of
the results is followed by a discussion (section X)
and a summary (section XI).
1 Of the 220 patients in the main analysis of this study,
62% were assessed as having cavitation on admission to
treatment and 12% as having extensive or gross disease.
These proportions are considerably smaller than those
quoted in earlier reports and give the impression that patients
in this study had less severe radiographic lesions than those
in earlier studies. However? there is evidence that these
differences are due to variations in the standards of inter-
pretation of radiographs. Thus, the 220 radiographs in the
present study had been assessed along with 324 other pre-
treatment radiographs (random sample) from previous
studies by the same independent assessor, who was unaware
of the study to which any individual patient belonged. He
reported cavitation in 63 % of the 324 patients and extensive
or gross disease in 15 %, proportions which are very similar
to those in the present study. Confirmatory evidence that
no change had occurred in the type of disease encountered
is provided by the finding that 89% of the patients in the
present study had a positive smear from a single collection
specimen of sputum on admission to treatment, as compared
with 85 % in the random sample from earlier studies.
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V. COMPARISON OF THE RESPONSE TO TREATMENT OF PATIENTS
IN THE THREE SERIES
DEATHS
Two patients died of tuberculosis, one (PH) in
the first week from pulmonary disease and the other
(TH), who had positive cultures with isoniazid-
resistant organisms at 3, 5 and 7 months, in the eighth
month from a space-occupying intracranial lesion,
believed to be a tuberculoma.
Six patients (2 PH, 4 TH) died of non-tuberculous
causes. Two chronic asthmatics (both PH), who
were under treatment for this condition, died in
status asthmaticus; of these, one died in the third
month having had positive cultures at two months,
and the other in the eleventh month having had
negative cultures persistently since the first month.
Three others (all TH) died of non-tuberculous
bronchopneumonia, bacillary dysentery and carci-
noma of the oesophagus, respectively, in the fourth,
seventh and seventh months, having had only
negative cultures since the second, third and fourth
months, respectively. The sixth patient (TH) died
suddenly in the third month, the cause of death
being uncertain (see page 502); she had had only
negative cultures since the first month. An autopsy
was not performed on any of the patients.
PREMATURE TERMINATION OF THE ALLOCATED
CHEMOTHERAPY OWING TO SERIOUS RADIOGRAPHIC
OR CLINICAL DETERIORATION
If a patient was considered by the Centre’s medical
staff to have, in the presence of a positive sputum,
definite radiographic extension of the disease which
had not been present at one month, a 10-day course
of penicillin was given. If the lesion persisted or
spread, the complete radiographic series was shown
to an independent assessor (Dr K. S. Sanjivi), who
decided whether a change of chemotherapy was
necessary.Eleven patients had their allocated
chemotherapy prematurely terminated on account
of serious radiographic deterioration, 3 PH patients
in the tenth, eleventh and twelfth months, 2 TH
patients in the fifth and ninth months and 6 P6H/H
patients in the sixth, eighth, tenth, eleventh, eleventh
and twelfth months, respectively.
Serious clinical deterioration was regarded as a
reason for termination of the allocated chemotherapy
without recourse to the independent assessor, and
two patients (1 TH, 1 P6H/H), both with a positive
sputum, had chemotherapy terminated for this
reason in the ninth and eleventh months, respectively.
DEPARTURES FROM THE ALLOCATED CHEMOTHERAPY
ON ACCOUNT OF TOXICITY
In three patients (1 PH, 1 TH, 1 P6H/H) the
allocated chemotherapy was terminated on account
of cutaneous hypersensitivity in the second, second
and third months, respectively. In three other
patients (all TH) there were departures from the
prescribed chemotherapy on account of hyper-
sensitivity, which started in the second, second and
third months and lasted for more than six weeks—
namely, for 43, 64 and 54 days, respectively. A
further patient (P6H/H) developed hypersensitivity
in the third month and, although he was successfully
desensitized, he subsequently became uncooperative
and had a departure from the allocated chemo-
therapy for more than six weeks.
DEPARTURE FROM THE ALLOCATED CHEMOTHERAPY
ON ACCOUNT OF NON-COOPERATION
Five patients (1 PH, 2 TH, 2 P6H/H) became
uncooperative and stopped treatment completely,
two (both TH) in the first, one (P6H/H) in the fourth,
one (P6H/H) in the sixth and one (PH) in the twelfth
month. Eight other patients (2 PH, 2 TH, 4 P6H/H)
did not collect drugs for periods of more than
six weeks.
POLICY FOR INCLUSION IN THE ANALYSES OF PATIENTS
WHO DID NOT RECEIVE THE ALLOCATED
CHEMOTHERAPY THROUGHOUT THE YEAR
Patients who died of tuberculosis and those whose
allocated chemotherapy was terminated owing to
deterioration have, in general, been included in the
analyses throughout the year except in theanalyses
of toxicity (Appendix Tables B and C) and regularity
of attendance (Table 15), where they have been
included only up to the time of death or termination;
furth rmore, patients who died of tuberculosis have
been included only up to the time of death in analyses
of isoniazid-sensitivity test results (Table 6). Patients
w o died of non-tuberculous causes, and those who
had their allocated chemotherapy terminated or
had a departure of more than six weeks owing to
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TABLE 3
CHANGES IN RADIOGRAPHIC APPEARANCES IN THE 12-MONTH PERIODa
No change 1 2 2
Slight 0 1 1
Deterioration
Moderate 0 2 1
Termination of allocated chemotherapy owing
to serious radiographic deterioration
Termination of allocated chemotherapy owing
to serious clinical deterioration, or tubercul-
ous death
Total patients b 66 65 63
a Assessment on standard radiographs taken on admission to treatment and at 12 months.
b The policy for including in the analyses patients who did not receive the allocated chemo-
therapy throughout the 12-month period is described in the text.
toxicity or noncooperation have, in general, been
included only up to the time of death, termination
of the chemotherapy or first major departure;
however, those who had a departure of more than
six weeks for any reason have been included through-
out in the analyses of toxicity (Appendix Tables B
and C).The policy set out above relates to Tables 3-6,
Table 15 and Appendix Tables B and C. The policy
for analyses relating response to treatment to factors
on admission (Tables 9 and 14) and for analyses of
PAS-sensitivity test results (Table 11) is described
in footnotes.
WEIGHT CHANGES
The average change in weight during the first
6 months was a gain of 9.4 lb for the PH, 5.3 lb for
the TH and 9.8 lb for the P6H/H patients and,
over the full 12-month period, 10.6 lb, 6.0 lb and
10.3 lb, respectively. (As many as 18% of the TH
patients lost weight over the 12-month period, as
compared with 3 % of the PH patients and 6% of
the P6H/H patients.) The difference between the
TH series and the other two series attains statistical
significance, both in the first 6 months and over the
12-month period (P<0.01).
RADIOGRAPHIC CHANGES
The changes in radiographic appearances were
evaluated by an independent assessor, Dr Raj
Narain, who was unaware of the treatment or any
other detail of any individual patient (Table 3).
Viewing the postero-anterior films taken. on ad-
mission and at 12 months, he assessed the improve-
ment as moderate or greater in 83% of the PH
patients, 77 % of the TH and 70% of the P6H/H
patients. Serious radiographic deterioration (neces-
sitating termination of the allocated chemotherapy)
occurred in 5 %, 3 % and 10 %, respectively. Thus,
the radiographic progress appeared to be best in
the PH series and least satisfactory in the P6H/H
serie . However, none of the differences is statisti-
cally significant.
Table 4 presents the changes in cavitation for the
12-month period as assessed by the independent
assessor on the basis of postero-anterior films taken
on admission and at 12 months. Cavitation dis-
appeared in 70% of the PH patients, 69 % of the
TH patients and 61% of the P6H/H patients and had
become less in 7 %, 18 % and 15 %, respectively.
Of 70 patients (22 PH, 26 TH, 22 P6H/H) who had
no cavitation on admission to treatment, 5 (2 PH,
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TABLE  4
CHANGES IN CAVITATION IN THE 12-MONTH PERIOD IN PATIENTS WITH CAVITATION ON ADMISSION
TO TREATMENTa
                Cavitation at 12 months in relation to cavitation
  Treatment                  on admission                            Termination of allocated
    series b    Total patients chemotherapy owing to serious
  Disappeared           Less Same More radiographicoclinicaldeterioration
No. % No.  % or tuberculous death
      PH        44 31 70 3 7     1      5 4
     TH        39 27 69 7 18      0       2 3
  P6H/H        41 25 61 6 15      2       2        6
    a Assessment on standard radiographs taken on admission to treatment and at 12 months.
  b
 The policy for including in the analyses patients who did not receive the allocated chemotherapy throughout the 12-month
     period is described on page 489.
2 TH, 1 P6H/H) had cavitation at 12 months and 2
(1 TH, 1 P6H/H) had their allocated chemotherapy
terminated on account of serious deterioration
during the year. Thus, the differences between the
three series were small, the response seeming to be
most satisfactory in the TH series and least satis-
factory in the P6H/H series.
SMEAR AND CULTURE RESULTS
The findings of smear and culture examination of
multiple specimens of sputum at monthly intervals
during treatment are presented in Table 5. The
intensity of the examination was similar in the three
series at every month of the year, the average number
of results per patient at each month varying from
2.7 to 2.9, as compared with the planned number of
3 (only specimens collected within a week of the set
date have been included).
It can be seen that there was a rapid and similar
increase during the first 4 months in the proportion
of patients with all cultures negative; thus, at
4 months, 79% of the patients in each of the three
series produced only negative cultures. Thereafter,
there was comparatively little change in the PH and
the TH series; however, in the P6H/H series, there
was evidence of a decline at 6 months, a point dis-
cussed further on page 499. Thus, the proportion of
patients with all cultures negative at 6 months was
79 % for the PH series, 81% for the TH series and
71% for the P6H/H series; the corresponding pro-
portions were 81%, 80 % and 63 % at 9 months and
82%, 82% and 66% at 12 months. Although the
differences between the P6H/H series and the other
two were fairly large at the end of the year of chemo-
therapy, they did not attain statistical significance
(0.05<P<0.1).
SENSITIVITY TESTS
Isoniazid
In Table 6, the results of isoniazid-sensitivity tests
are set out monthly for the first 9 months, and for
12 months. (Results were not available in only 12
(1.7%) of 709 cultures.) From the fifth month
onwards, an increasing number of patients had their
allocated chemotherapy terminated on account of a
serious radiographic or clinical deterioration. In all,
there were 13 such patients, 12 of whom were
excreting isoniazid-resistant organisms at the time
of the termination (all 12 had produced a resistant
culture on at least four occasions); excluding them
thereafter would have the effect of underestimating
the incidence of isoniazid resistance at later months
with the allocated chemotherapy. Consequently,
the assumption has been made that the 12 patients
with resistant organisms at the time of termination
of the allocated chemotherapy would have continued
to excrete resistant organisms subsequently had their
treatment not been changed. A consolidated total of
patients with resistant strains was therefore obtained
at each month by adding the number of patients with
a resistant culture (column C) to the number who
had chemotherapy terminated on account of
deterioration (column D). This total has then been
expressed as a percentage of (1) the total patients
with sensitivity results available (column B) plus the
patients whose chemotherapy was terminated
(column D), and (2) the total patients under study
(column A).
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TABLE 5
PRESENCE OF TUBERCLE BACILLI IN MULTIPLE SPECIMENS OF SPUTUM
TAKEN AT MONTHLY INTERVALS
Months
after start
of chemo-
therapy
1
2
3
4
5
6
7
8
9
10    
11
12
Treatmen
series
t Total
patients a
PH
TH
P6H/H
72
75
69
PH
TH
P6H/H
11
72
69
PH
TH
P6H/H
PH
TH
P6H/H
69
70
68
68
66
66
PH 68
TH 67
P6H/H 65
PH
TH
P6H/H
68
67
63
PH
TH
P6H/H
68
65
63
PH
TH
P6H/H
68
65
63
PH
TH
P6H/H
68
65
63
PH
TH
P6H/H
68
64
63
PH
TH
P6H/H
67
65
63
PH 66
TH 65
P6H/H 62
Termination
of allocated
chemotherapy owing
to serious radiographic
or clinical deterioration
or tuberculous death
1
0
0
1
0
0
1
0
0
1
0
0
1
1
0
1
1
1
1
1
1
1
2
2
1
4
2
2
4
3
3
4
6
4
4
7
At least
me culture
positive
63
65
60
41
40
40
22
22
20
13
14
14
14
8
14
13
12
17
15
10
16
9
14
18
12
9
21
10
7
17
9
8
12
8
8
14
All cultures
negative b
No. %
8 11
10 13
9 13
29 41
32 44
29 42
46 67
48 69
48 71
54 79
52 79
52 79
53 78
58 87
51 78
54 79
54 81
45 71
52 76
54 83
46 73
58 85
49 75
43 68
55 81
52 80
40 63
56 82
53 83
43 68
55 82
53 82
45 71
54 82
53 82
41 66
a The policy for including in the analyses patients who did not receive the allocated chemo-
therapy throughout the 12-month period is described on page 489.
b Even If the smears were positive.
COMPARISON OF THREE DUAL-DRUG REGIMENS IN HOME TREATMENT OF TUBERCULOSIS
I -
t
I
-
494 TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS
Considering first the former percentages, there
was a higher incidence of resistant strains in the early
months in the TH series, increasing from 5% at
1 month to 18 % at 2 months and 41% at 3 months.
The corresponding proportions for the PH series
were 3 %, 2% and 14% respectively, and for
the P6H/H series 3%, 10% and 25%, respectively.
By 4 months, however, the proportions in the PH
and the P6H/H series had overtaken that in the TH
series; thus the proportion with resistant cultures
was 46 % for the PH series, 38 % for the TH series
and 50% for the P6H/H series. At the end of 6
months of treatment, 92% of 12 cultures in the PH
series were resistant, as compared with 67 % of 12 in
the TH series and 83 % of 18 in the P6H/H series.
Subsequently, the great majority of cultures in the
PH and the P6H/H series were resistant, the figures
being 88 % of a total of 67 and 97% of a total of
118, respectively (including results at 10 and 11
months which have not been tabulated here for
reasons of space). In contrast, only 67% of a total
of 63 cultures in the TH series were resistant, the
proportion ranging between 60% and 70 % at the
individual months; this difference was largely due to
three patients in the TH series who persistently had
positive cultures with sensitive organisms (see
below).
Considering next the incidence of isoniazid
resistance expressed as a percentage of total patients
in the study, the findings in the early months were
similar-namely, a higher incidence in the TH series.
Thus, the proportion with resistant cultures was 1 %
in the PH series, 10 % in the TH series and 6 % in the
P6H/H series at 2 months, and 4 %, 13 % and 7 %,
respectively, at 3 months. Thereafter, this propor-
tion continued to increase in the PH series up to
6 months, remained fairly constant in the TH series,
and increased in the P6H/H series up to 9 months.
At 12 months, the proportions were 17%, 11% and
34 %, respectively.
In summary, isoniazid resistance emerged earlier
in the TH series than in the PH or the P6H/H series.
The proportions of patients with a resistant culture
at 6 months were 16 % in the PH, 12 % in the TH and
24 % in the P6H/H series. Thereafter, the proportion
remained fairly constant for the PH and the TH
series, but continued to increase in the P6H/H s ries.
Emergence of resistance. Resistance to isoniazid
emerged during treatment in 22 (31%) of the 72 PH
patients, 25 (32%) of the 77 TH patients and 27
(38%) of the 71 P6H/H patients. Of these 74 patients,
26 (8 PH, 14 TH, 4 P6H/H) produced a resistant
culture on only one occasion; the resistant culture
was p oduced after sputum conversion (that is,
three consecutive months of culture negativity) in
11 patients (4 PH, 7 TH) and before sputum con-
version in the remaining 15 (4 PH, 7 TH, 4 P6H/H).
At least two resistant cultures were produced by 14
(19%) PH, 11 (14%) TH and 23 (32%) P6H/H
patients. This was followed by sputum conversion
in 2, 3 and 1 patients, respectively; however, one
patient in each series subsequently had a bacterio-
logical relapse with isoniazid-resistant organisms.
There were 146 patients (50 PH, 52 TH, 44 P6 /H)
w o did not produce even one resistant culture
during the year. Of these, three (all TH) persistently
had positive cultures with isoniazid-sensitive organ-
isms; one produced positive cultures at each month
th oughout the year except the third and the twelfth,
another from the fifth to the twelfth month inclusive,
the third from the first to the eighth month
inclusive when treatment was changed on account of
seri us radiographic deterioration. All three patients
had be n veb irregular in taking their drugs, as 56 %,
90% and 82 %, respectively, of their clinic urine
specimens, and 78%, 57 % and 75 %, respectively,
of urine specimens collected at surprise visits to the
hom , yielded a negative result when tested for the
presence of isoniazid.
Thioacetazone
Pretr atment sensitivity results. Thioacetazone-
sensitivity test results were available on duplicate
pretreatment cultures from each of
(a) 209 patients (71 PH, 75 TH, 63 P6H/H), using
the standard inoculum, and
(b) 168 patients (55 PH, 64 TH, 49 P6H/H), using
a dilute inoculum (1 : 20).
The correlation between the results of duplicate
cultures is summarized in Table 7 for both types of
test. Identical results or results differing by a single
2-fold dilution step were obtained for 82% of the
patients using the standard inoculum, as compared
with 86% using the dilute inoculum. Further, the
difference was 4 dilution steps or greater in 7% of
the former tests, as compared with 1% of the latter.
Thus, the correlation was slightly less good with the
standard inoculum than with the dilute inoculum—
the mean difference between results of duplicate
cultures being just less than 1 dilution step with the
standard inoculum as compared with approximately
two-thirds of a dilution step with the dilute inoculum;
the contrast attains statistical significance (P = 0.02).
(This conclusion was confirmed in the subgroup of
COMPARISON OF THREE DUAL-DRUG REGIMENS IN HOME TREATMENT OF TUBERCULOSIS 495
TABLE 7. COMPARlSON OF THIOACETAZONE-SENSITIVITY TABLE 8. RESULTS OF THIOACETAZONE-SENSITIVITY
TEST RESULTS IN DUPLICATE PRETREATMENT TESTS IN ALL PATIENTS ON ADMISSION TO TREATMENT
CULTURES FROM THE SAME PATIENT
Difference between
results of duplicate
cultures
(No. of 2-fold dilution steps)
Standard
inoculum
Dilute inoculum
(1 : 20)
92 44 84 50
Less than 0.5
79 38
16 8
7 3
8 4
4 2
3 1
61 36
0.5-
15 9
1.0-
6 4
2.0-
1 1
4.0-
1 1
8.0-
0 0
16.0-
32.0-
Total 209 100 168 101 64.0 or more
No. of         %
patients
17 8
23 11
53 25
69 33
18 9
10 5
10 5
5 2
4 2
I
No. of       %
patients
24 14
26 15
70 42
40 24
6 4
2 1
0 0
0 0
0 0
Mean 0.97 0.70 Total 209 100 168 100
168 patients, who had sensitivity test results for two
cultures, both with the standard inoculum and with
the dilute inoculum tests.) Examination of the
results by analysis of variance indicated that both
types of test were capable of distinguishing variation
from patient to patient in the thioacetazone sensi-
tivity of their strains; the standard inoculum test
appeared slightly more efficient than the dilute
inoculum test in this differentiation.
In view of the wide variability in the results of
duplicate cultures from the same patient, the
geometric mean of the MICs of two pretreatment
cultur s was calculated for each patient. Table 8
sets ut the distribution of patients according to
these means, both for the standard inoculum and for
the dilute inoculum. Neither of the distributions
sugg s any obvious definition of thioacetazone
resistance.
Pretreatment thioacetazone sensitivity and response
to treatment in the TH series. Table 9 relates pre-
TABLE 9. RESPONSE TO TREATMENT IN THE TH SERIES RELATED TO THIOACETAZONE SENSITIVITY
ON ADMISSION TO TREATMENTa
Geometric mean
of MlCs for
two pretreatment
cultures
(µg/ml)
Standard inoculum
Total patients b
Favourable Unfavourable
response c response c Total patients 
d
Less than 1.0 16 14 2 22
1.0- 1 1 9 2 23
2.0- 19 16 3 17
4.0- 9 9 0 0
8.0- 4 2 2 1
16.0- 3 2 1 0
32.0 or more 3 1 2 2
Dilute inoculum (1 : 20)
Favourable
responses
Unfavourable
response c
18
19
16
0
0
0
0
65 53 12 65 53 12Total
a Excluding patients who died of a non-tuberculous cause and those who had a termination of the allocated chemotherapy,
or a departure of over six weeks, on account of toxicity or non-cooperation.
b Including two patients for whom only one pretreatment sensitivity result was available.
c For definition, see page 497. d Including 10 patients for whom only one pretreatment sensitivity result was available.
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treatment thioacetazone sensitivity, expressed as the
geometric mean of the MICs of two pretreatment
cultures, to response to treatment in the TH series.
There was a tendency for patients with initially less
sensitive strains to respond unsatisfactorily to treat-
ment. Thus, with the standard inoculum results,
the patients with an unfavourable response had a
pretreatment geometric mean of 3.98 µg/ml, as
compared with 1.83 µg/ml for patients with a
favourable response, the contrast just attaining
statistical significance (P = 0.05). With the dilute
inoculum results, the corresponding figures were
1.94 µg/ml and 0.98 µg/ml, respectively (P = 0.04).
Sensitivity results during treatment in the TH series.
Owing to difficulties in identifying patients with pre-
treatment thioacetazone-resistant strains, the results
of sensitivity tests at monthly intervals during treat-
ment are not presented here for all TH patients, as
has been done in the case of isoniazid. However,
the detailed findings of tests with the standard
inoculum are presented in Table 10 for those TH
patients who had an unfavourable response to
treatment, since they are the patients in whom
resistance is most likely to have emerged.
An examination of these findings suggests that
resistance to thioacetazone emerged in only one
patient (R 231), and possibly in another (R 146).
Thus, there was little evidence of the emergence of
resistance in strains from individual patients in the
TH series. (Similar conclusions were drawn from the
results (not tabulated here) of the dilute inoculum
tests.)
PAS
The first pretreatment culture was considered to
be PAS-resistant for 11 (8%) of 142 patients—
namely, 4 of 72 in the PH series and 7 of 70 in the
P6H/H series (Table 11). Of these, 5 cultures (4 with
a resistance ratio (RR) of 8 and 1 with an RR of 16)
were retested and all yielded an RR of 2 or less.
Of the above 11 patients, 9 (82%) were classified at
6 months as having a favourable response to treat-
ment (for definition, see Table 13), as compared
with 95 (78%) of 122 patients with sensitive organ-
isms whose response could be assessed. Further,
both pretreatment cultures were considered to be
resistant in only two patients, both of whom were
classified as having a favourable response at
6 months. These findings suggest that, in all likeli-
hood, most or all of the 11 patients really had PAS-
sensitive strains on admission to treatment.
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TABLE 11
RESULTS OF PAS-SENSITIVITY TESTS ON ADMISSI0N, a AT 6 AND AT 12 MONTHS
497
Months after start
of chemotherapy
0
6
(or 7 or 5)
12 (or 11)
Treatment series
PH
P6H/H
Both series
PH
P6H/H
Both series
PH
P6H/H
Both series
Total patients
receiving allocated PAS-resistant
chemotherapy with PAS-sensitive
sensitivity test results
available b No. %
16 17
19 17d
37 34
10 7
15 12d
25 19
1 (6) c
2 (11)
3 8
3 d (30)
3 (20)
6 24
a Based on the results of the first specimen.
b Patients who died, those who had a termination of the allocated chemotherapy and those who
had a departure of over six weeks, for any reason, have been included up to the time of death, ter-
mination and the first major departure, respectively.
c The parentheses indicate percentages based on fewer than 25 observations.
d Including one patient whose allocated chemotherapy was terminated at this month owing to
serious radiographic-deterioration.
Considering next the results at 6 months, 3 (8 %) of
37 patients had a resistant culture. At 12 months,
the corresponding figures were 6 (24%) of 25; all of
these six had had PAS-sensitive strains on admission.
Thus, PAS resistance had not emerged at 6 months
but had emerged in a small proportion of patients
at 12 months.
CLASSIFICATION OF PATIENTS AT 12 MONTHS
ACCORDING TO THEIR RESPONSE TO TREATMENT
Table 12 presents a classification of all the patients
at 12 months, based primarily on the bacteriological
response to treatment. The proportion of patients
who had bacteriologically quiescent disease at one
year was 77% for the PH series, 78% for the TH
series and 65 % for the P6H/H series. There were six
patients (3 PH, 2 TH, 1 P6H/H) who had disease of
bacteriologically doubtful status at one year. In view
of the intensity with which sputum specimens are
examined at the Centre (see page 486) and previous
experience with similar groups of patients (Velu et
al., 1960, 1961; Devadatta et al., 1961; Dawson
et al., 1966 1), these patients have been regarded
1 See article on page 533 of this issue.
as having a favourable response to treatment. (A
follow-up of the patients showed that all six pro-
duced only negative cultures in the six months
i mediately following the single positive culture.)
Thus, 82 % of 66 PH patients, 82% of 65 TH
ts and 67% of 63 P6H/H patients had a
favourable response. The difference between the
P6H/H series and the other two, although fairly
large (15 %), does not attain statistical significance
(0.05<P<0.1).
An unfavourable response to treatment-that is,
death from tuberculosis, or bacteriologically relapsed
or active disease at 12 months (including premature
termination of the allocated chemotherapy for
serious radiographic or clinical deterioration)–
occurred in 18 % of the PH patients, 18 % of the TH
patients and 33% of the P6H/H patients.
In the above totals, 26 patients (6 PH, 12 TH,
8 P6H/H) have not been included for reasons
given in the lower part of the table. It was not
possible to assess the therapeutic efficacy of the
regimens in 10 of these patients, namely, six who
died of non-tuberculous causes (see page 489), three
whose chemotherapy was terminated on account of
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TABLE 12
CLASSIFICATION OF ALL PATIENTS AT THE END OF 12 MONTHS ACCORDING
TO THEIR RESPONSE TO TREATMENT
Treatment series
Classification at the end of 12 months PH TH P6H/H
No. % No. % No. %
4 6 5
13 15 14
12 6 1 1
6 10 5
4 3 1
2 0 0
3 2 2
4 0 1
1 6 0
2 3 2
First month of persisting culture
negativity
1
2
3
4
5
6
7
3
9
10
Total 51 77 51 78 41 65
Patients with disease of bacteriologically doubtful status:
that is, patients whose cultures were all negative at three or more consecutive
monthly examinations but who produced a single positive culture at one of the last
three monthly examinations–i.e., at 10, 11 or 12 months 3 5 2 3 1
54 82 53 82 42 67
Patients with bacteriologically relapsed disease:
that is, patients whose cultures were all negative at three or more consecutive
monthly examinations, but who produced a total of two or more positive cultures
in the last three monthly examinations-i.e., at 10, 11 and 12 months 2 3 5 8 6 13
Patients with bacteriologically active disease:
that is, (a) patients whose cultures were never all negative at three consecutive
monthly examinations
or (b) patients who had their allocated chemotherapy terminated on account
of serious radiographic or clinical deterioration
6 9
3 5
1 2
3 5
3 5
1 2
6 10
7 11
0 0
12 18 12 18 21 33
66 100 65 100
1  –
2  –
2  –
2  –
Patients who, on account of toxicity, had:
(a) their allocated chemotherapy terminated
or (b) a departure from the allocated chemotherapy for more than six weeks
1  –
0  –
2  –
1  –
3  –
4  –
72        – 77        –
63 100
2  –
4  –
1  –
1  –
0  –
71            –
Patients with bacteriologically quiescent disease:
that is, patients whose cultures were all negative
for at least the last three monthly examinations–
i.e., at 10, 11 and 12 months
Total patients with a favourable response
Tuberculous deaths
Total patients with an unfavourable response
Total
Patients who became uncooperative and:
(a) refused further treatment
or (b) received no treatment for more than six weeks
Non-tuberculous deaths
All patients
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toxicity within three months of starting treatment
and one (TH) who refused to attend the clinic after
the first month. Of the remaining 16 patients (3 PH,
6 TH, 7 P6H/H), one (TH) died of tuberculosis in
the ninth month; for the other 15, it was possible to
assess the response on the basis of 2-9 (average of 7)
culture results in the last 3 months of the year, a
favourable response being observed in 8 patients
(1 PH, 3 TH, 4 P6H/H). If these 16 patients are taken
into consideration in assessing the therapeutic
efficacy of the three regimens, the proportion of
patients with a favourable response becomes 80%
for the PH, 79 % for the TH and 66% for the
P6H/H series; again, the differences between the
P6H/H series and the other two are not statistically
significant (P ~ 0.1).
In summary, the therapeutic efficacies of the PH
and TH regimens were very similar. The P6H/H
regimen was inferior, although the difference was not
statistically significant.
RESPONSE TO TREATMENT IN THE PH AND THE P6H/H
SERIES DURING THE FIRST 6 MONTHS
In the preceding pages, it has been reported that
the response to the P6H/H regimen over the 12-
month period was inferior to that to the PH regimen,
both radiographically and bacteriologically. The
extent to which this finding was influenced by the
differences between the regimens in drug-composition
in the first 6 months (see Table 1 and Appendix
Table A) is studied below.
Considering radiographic changes, there was
moderate or greater improvement in 79% of 68 PH
patients, as compared with 76% of 63 P6H/H
patients, including considerable or exceptional
improvement in 9 % and 22 %, respectively. Serious
radiographic deterioration (necessitating termination
of the allocated chemotherapy) occurred in 0% and
2 %, r spectively. Cavitation disappeared in 66 % of
44 PH patients, as compared with 78 % of 41 P6H/H
patients, while it became less in 18 % and 17 %,
respectively.
The proportions of patients who produced only
negative cultures from multiple specimens of
sputum (usually 3) were very similar for the two
series at each month up to five months (see Table 5),
at which time 78 % of the patients in both series had
only negative cultures. While this proportion was
prac ic lly the same at six months in the PH series,
there was a fall to 71% in the P6H/H series. The
TABLE 13
RESPONSE TO TREATMENT DURING THE FIRST SIX MONTHS
Response to treatment
PH patients
No. %
Favourable All cultures (usually 6) negative at five and six months 49 72
All cultures negative at six months but at least one positive culture
at five months 5 a
Doubtful 12
One positive culture at six months but all cultures negative at five
3 a
Total of two or more positive cultures at five and six months, at least
Unfavourable
one of these being at six months 10
16
Termination of allocated chemotherapy owing to serious radio-
graphic deterioration, or tuberculous death 1 i
Total 68 100
Patients who died of a non-tuberculous cause or who, on account of toxicity or non-
cooperation, had a prolonged departure from or termination of the allocated chemo-
therapy 4  –
All patients 7 2  –
a Including three patients whose response was finally classified as favourable (see text).
b This patient was finally classified as having a favourable response.
c Including two patients whose response was finally classified as favourable.
P6H/H
patients TH patients
No. % No. %
46 70 54 81
66 101 67 100
5     –    10    –
71   –         77    –
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decrease in the P6H/H series was accounted for by
six patients having all cultures negative at five
months and at least one positive culture at six months,
as compared with only one patient having all cultures
negative at six months and at least one positive
culture at five months (the corresponding numbers
in the PH series were four and five, respectively).
Further examination of the data showed that in four
of the seven P6H/H patients, the result observed was
unusual-for example, an isolated positive result
among a series of negative results (this was also the
case in five of the nine patients in the PH series). In
order to obtain a clearer picture of the findings, a
more comprehensive classification of response, based
on culture results at five and six months, was
therefore undertaken; the findings are presented in
Table 13.
of 66 P6H/H patients. In 13 patients (8 PH, 5 P6 /H),
the response was classified as doubtful; however, a
consideration of the results at 7 months suggested
tha  10 (6 PH, 4 P6H/H) of these patients could also
be classified as having had a favourable response, so
that the over-all numbers of patients with favourable
response are 55 (81%) for the PH series and 50
(76 %) for the P6H/H series.
In summary, the response of the PH and the
P6H/H patients during the first 6 months was fairly
similar, the latter showing slightly better radio-
graphic response but slightly inferior bacteriological
response. These findings, taken in conjunction with
those over the 12-month period, suggest that the
relatively poor therapeutic response in the P6H/H
seri s at 12 months was due to giving only isoniazid
in the second 6 months of treatment.
In all, 72% of 68 PH patients had a bacterio-The findings for the TH patients have also been
logically favourable response, as compared with 70 %included in Table 13 for the sake of completeness.
TABLE 14
RESPONSE TO TREATMENT RELATED TO VARIOUS FACTORS ON ADMISSION TO TREATMENTa
Condition on admission
to treatment
Extent of cavitation:
Extensive or moderate
Slight or nil
Total extent of disease:
Gross, extensive or moderate
Limited or slight
Number of lung zones:
6, 5 or 4
3, 2 or 1
Bacterial content of sputum: d
3-plus or 2-plus
1-plus or negative
Total patients
PH series
Total
patients
31
35
32
34
52
14
41
2.5
66
Unfavourable
response b
No. %
Total
patients
10 32 28
2 6 37
11 34
1 3
10 24
2 8
12
TH series P6H/H series
65
Unfavourable
response b Total
patients
No. %
5 18 29
7 19 34
6 19 30
6 18 33
11 24 42
1 (5) 21
5 13 34
7 26 29
12 63
Unfavourable
response b
No. %
14 48
7 21
15 50
6 18
16 38
5 (24)
14 41
24
21
a Excluding patients who died of a non-tuberculous cause, and those who had a termination of the allocated chemotherapy
or a departureof over six weeks, on account of toxicity or non-cooperation.
b For definition, see page 497.
c The parentheses indicate percentages based on fewer than 25 observations.
d Direct smear result on first or only collection specimen.
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VI. RESPONSE TO TREATMENT RELATED TO. VARIOUS FACTORS ON ADMISSION
TO TREATMENT
Of 39 PH patients who were under 35 years of age,
10% had an unfavourable response to treatment, as
compared with 30 % of 27 who were aged 35 years or
above; the corresponding proportions were 11% of
37 and 29 % of 28 in the TH series, and 29 % of 34
and 38 % of 29 in the P6H/H series. Thus, the older
patients in all three series had a relatively poor
response to treatment; however, the association
attained statistical significance only in the PH series,
in which further analysis showed that the patients
aged 35 years or above had more extensive disease
initially than those below 35 years, as assessed by
the total extent of disease, extent of cavitation and
number of lung zones involved in disease. There was
no association between sex and response to treatment
in any of the series.
Table 14 relates other assessments of condition on
admission to the response to treatment. It can be
se  that, both in the PH and in the P6H/H series,
the likelihood of an unfavourable response was
greater for patients with extensive or moderate
cavitation, for those with gross, extensive or moder-
ate disease, for those with 4 or more lung zones
involved in disease and for those with a moderately
r heavily positive smear on a single collection speci-
men of sputum; however, in both series, the associa-
tion was statistically significant only for cavitation
and total extent of disease. In contrast, in the
TH series, neither cavitation nor total extent of
d sease was of prognostic value, although patients
with 4 or more lung zones involved in disease
had a greater likelihood of unfavourable response;
this association was not statistically significant
(P>0.1).
VII. TOXICITY AND OTHER COMPLICATIONS
DRUG TOXICITY difference between the TH and the P6H/H series was
Of the 220 patients in the main analysis, one
statistically significant (P=0.02) while that between
(PH) who died in the first week of treatment and two
the TH and the PH series was not (P>0.1).
(both TH) who refused further treatment in the first
Complaints of giddiness were made by 4% of the
and third weeks have been excluded from the analysis
PH, 28 % of the TH and 10 % of the P6H/H patients,
of drug toxicity as they had been under treatment for
the differences between the TH series and the other
so short a period; none of these three patients had
two being highly significant (P < 0.01).
complained of toxicity. There remain 71 PH, 75 TH
and 71 P6H/H patients in the analyses.
Gastrointestinal and other complaints
Only spontaneous complaints were recorded and
patients were not questioned to elicit symptoms.
A complaint of vomiting, with or without diarrhoea,
was recorded on at least one occasion in 8% of the
71 PH patients, 23 % of the 75 TH and 15 % of the 71
P6H/H patients; the difference between the PH and
the TH series attains statistical significance (P=0.03).
In 2 PH, 2 TH and 2 P6H/H patients, the complaints
were so persistent that treatment had to be interrup-
ted for 7, 35, 7, 35, 15 and 38 days, respectively.
Anorexia occurred in 7 % of the PH patients, 17 %
of the TH and 4% of the P6H/H patients; the
Cutaneous hypersensitivity
Cutaneous hypersensitivity reactions occurred in
4 (6 %) of the 71 PH patients (3 in the second and 1 in
the third mouth), 5 (7 %) of the 75 TH patients (3 in
the fir t and 2 in the second month) and 1 (1%) of
t e 71 P6H/H patients (in the second month).
Desensitization was successful in three of the PH
and four of the TH patients but unsuccessful, even
under cover of corticosteroids, in one of the PH
patients and in the P6H/H patient; in one TH patient
it was not attempted, since the rash persisted even
after thioacetazone was stopped.
Of the five TH patients, two had a Stevens-Johnson
syndrome including one with very extensive exfolia-
tive dermatitis; both were extremely ill and required
502 TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS
urgent hospital admission. Two other TH patients
had early exfoliative dermatitis. The fifth TH
patient, the four PH patients and the P6H/H patient
had discrete papular rashes.
Liver toxicity
Jaundice occurred in 2 (3%) of the PH patients
(1, with concurrent urticaria (not included under
cutaneous hypersensitivity), in the second month and
1 in the eleventh month), in 2 (3 %) of the TH patients
(in the seventh and eighth months), and in none of
the P6H/H patients. The two PH patients resumed
treatment after interruptions of 14 and 37 days and
one of the TH patients after 29 days. The other
TH patient had also a serious clinical deterioration
warranting a change of treatment; however, on
account of the jaundice and a high serum GOT
(132 Karmen units), the change was not effected
until after 18 days.
In order to study the effect of thioacetazone on
hepatic function, serum GOT levels were determined
on admission to treatment and at 3, 9 and 12 months
in the TH series, and also in the P6H/H series as a
control. (The detailed findings are presented in the
upper half of Appendix Table B.) The average
serum GOT levels (Karmen units) on admission were
similar in the two series, namely, 21.3 (range 8-41)
and 21.8 (range 6-51), respectively. The average
levels were 22.9 for the TH series and 24.3 for the
P6H/H series at 3 months, 23.2 and 28.9 at 9 months,
and 28.2 (range 10-68) and 29.9 (range 16-54) at
12 months, respectively. Thus, at the end of the year
of treatment, there was a similar and statistically
highly significant (P<0.001) rise in both series.
Although the great majority of routine serum GOT
values during treatment lay well within the range of
pretreatment values, 2 TH patients and 8 P6H/H
patients had a value between 51 and 75 units on a
single occasion, but none had clinical evidence of
liver damage. One patient (TH) had a value of
90 units at 3 months and developed jaundice in the
seventh month; another (P6H/H) had a serum GOT
level of 115 units at 9 months while receiving
isoniazid alone, but had no clinical evidence of liver
toxicity.
A urine test for urobilin was performed weekly
and produced a positive result in three (4%) of the
PH patients, none of the TH patients and three (4 %)
of the P6H/H patients, each on one occasion.
Haemopoietic side-effects
To study the effect of thioacetazone on haemo-
poiesis, certain haemotological examinations were
undertaken on admission to treatment and at 3, 9
and 12 months for patients in the TH series and, as a
control, for those in the P6H/H series. For patients
in the PH series, the investigations were undertaken
only on admission and at 12 months. (The detailed
findings are presented in Appendix Table C.)
Haemoglobin and packed cell volume (PCV) . The
average haemoglobin value on admission was low,
being 11.7 g per 100 ml for the PH, 11.5 g per 100 ml
for the TH and 10.9 g per 100 ml for the P6H/H
seri s. At 12 months, it had increased by 1.6 g in
the PH series (P<0.001), 0.9 g in the TH (P<0.05)
and 2.1 g in the P6H/H series (P<0.01). The PCV
values showed similar trends, the increase over the
12-m th period being statistically highly significant
in all three series (P < 0.01).
Leucocytes. The average total leucocyte counts on
admission were similar in the three series, namely,
9800 cells/mm3 in the PH, 9700 in the TH and 9500
in the P6H/H series. During the year, the average
count fell in all three series (P<0.001), being 8100,
7700 and 7100, respectively, at 12 months. This fall
was due to a decrease in the average number of
polymorphonuclear cells, from 6300 to 4300 in the
PH, from 6900 to 4800 in the TH and from 6800 to
4000 in the P6H/H series.
One patient (TH) complained of a sore throat and
a swollen ankle seven weeks after the start of treat-
ment and had by that time lost 11 lb (5 kg) in weight.
She was diagnosed as having acute filariasis and con-
tinued with her initial chemotherapy. The differen-
tial leucocyte count was later reported as poly-
morphonuclear cells 390 (5%), lymphocytes 4600
(59 %), eosinophils 2400 (31%) and monocytes 390
(5 %) cells/mm3. She died suddenly at home nine
weeks after admission, having coughed up a “ mass
of sputum ” and become very dyspnoeic. Although
the clinical course was unusual, in the absence of an
autopsy,agranulocytosis due to thioacetazone
cannot be excluded.
Glycosuria
Urine specimens of all patients were tested for the
presence of sugar (Benedict’s test) before admission
to the study; only two (1 TH, 1 P6H/H) had a
positive result, both being trace reactions. During
the year of treatment, some TH patients gave
positive results (in a sample of three patients, the
sugar was identified chemically as glucose), and it
was therefore decided subsequently to examine, at 6,
11 and 12 months, urine specimens for sugar from
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patients in the TH series and, as a control, from
those in the P6H/H series. The average number
of specimens examined per patient was 1.6 in the TH
series and 1.7 in the P6H/H series, the number of
patients with one or more routine examinations
during treatment being 65 and 61, respectively. The
test result was positive in at least one specimen
during treatment in 20 (31%) of the TH patients, as
compared with 8 (13 %) of the P6H/H patients, a
statistically significant difference (P = 0.03); there
was more than a trace in 8 (12 %) of the TH patients,
as compared with 2 (3%) of the P6H/H patients
(P> 0.1). Glucose tolerance tests performed on
three TH patients who had a strongly positive urine
test result for sugar were within normal limits.
Of the 20 TH patients in whom sugar was detected
during treatment, only 15 had a positive result at
the last test during the year of treatment. Urine
tests were undertaken in 14 of these after the thio-
acetazone had been stopped; 13 had negative results
while one produced a trace result on two occasions.
Neurological side-effects
Neurological side-effects attributed to isoniazid
were not encountered in the PH series, but one TH
patient (slow inactivator of isoniazid) had a sudden
loss of consciousness for about one hour in the seventh
month and one P6H/H patient (slow inactivator)
developed symptoms of peripheral neuropathy in
the third month. (One patient (TH), a slow inacti-
vator of isoniazid who has been excluded from the
main analysis on account of primary isoniazid
resistance, developed peripheral neuropathy in the
fourth month.)
GOT levels on whole blood were performed rou-
tinely in the TH and the P6H/H series on admission
and at 3, 9 and 12 months to study if there was any
evidence of isoniazid toxicity manifested by depres-
sion of the blood transaminase activity (Krishna-
murthy et al., in preparation). (The detailed findings
are presented in the lower half of Appendix Table B.)
The average levels of blood GOT on admission
to treatment were similar, namely, 598 units (range
271-1223) for the TH patients and 602 units (range
308-1043) for the P6H/H patients.In the TH patients,
there was a fall of 69 units in the average level at
3 months, followed by a gradual rise at 9 and at
12 months. Even so, the level at 12 months was
still significantly lower than that on admission
(P<0.05). In the P6H/H series, there was a fall of
27 units in the average GOT level at 3 months, but in
contrast to the findings in the TH series, the average
level at 9 months and at 12 months was similar to
the lev l at the start of treatment. Six patients had
GOT l vels of less than 300 units during treatment
(each on one occasion), namely, 261, 261 and 298 at
3 months and 287 at 9 months in 4 TH patients, and
298 at 3 months and 287 at 12 months in 2 P6H/H
ti t . The TH patient with a level of 298 at
3 months had the transient loss of consciousness
r ferred to above. In summary, there was a signi-
ficant depression of the mean blood GOT level over
the 12 months in the TH series, which was greatest
at 3 months; although the P6H/H series also showed
a depression of the mean level at 3 months, full
recovery to the pretreatment level had occurred by
12 months.
COMPLICATIONS REQUIRING ADMISSION TO HOSPITAL
OR SANATORIUM
Sixteen patients were admitted to hospital or
sanatorium on one or more occasions on account of
p lmo ary tuberculosis. Of these, 10 (1 PH, 7 TH,
2 P6H/H) were admitted, on account of serious
clinical deterioration, for total periods of 6 weeks,
5 days, and 3, 4, 9, 11, 12, 14, 10 and 13 weeks,
respectively. Five others (1 TH, 4 P6H/H) were
admitt d for 4, 5, 7, 8 and 18 weeks, respectively, on
account of spontaneous pneumothorax. The 16th
patient (P6H/H) was admitted for 2 weeks following
severe haemoptysis.
Seven patients were admitted on one or more
occasions on account of toxicity to the antitubercu-
losi drugs; of these, 4 (3 TH, 1 P6H/H) were
admitted for total periods of 1, 2, 15 and 3 weeks,
espectively, on account of severe skin reactions.
The remaining 3 (2 PH, 1 TH) were admitted for 7,
10 and 22 weeks, respectively, for intractable
vomiting and diarrhoea ascribed to drug intolerance;
the TH patient had a spontaneous pneumothorax
also.
Sixteen other patients (3 PH, 8 TH, 5 P6H/H) were
admitted for non-tuberculous illnesses for total
periods ranging from 1 day to 6 weeks (average
2 week ).
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VIII. ACCEPTABILITY OF REGIMENS AND CO-OPERATION OF PATIENTS
ACCEPTABILITY OF REGIMENS
In previous studies at the Centre (Tuberculosis
Chemotherapy Centre, Madras, 1959, 1960, 1963a,
1963b), two methods were used to check whether
patients were taking their drugs regularly, and to
compare the regularity of self-administration of
drugs in the different series. These were:
(1) tests to detect the presence of the drugs in
urine specimens collected at routine visits to the
Centre and at surprise visits to the home, and
(2) counts of the patient’s stock of cachets or
tablets at surprise visits to the home.
Both methods were undertaken in the present study
also (see page 486).
Urine tests
On account of the differences in the daily dosages
of both isoniazid and PAS and the different rhythms
in which the drugs were administered, the inter-
pretation of the test results varied for the three
regimens.It has therefore not been possible to
compare the regularity of self-administration of
drugs in the three series.
Despite these difficulties, the urine test results
can be used to compare degrees of irregularity
between patients in the same series. In all three
series, there was considerable variation between the
patients in the regularity with which they took their
drugs (as assessed by the results of tests on clinic
urine specimens collected at routine weekly visits);
however, there was no clear evidence in any of them
that this was associated with the outcome of treat-
ment (the results have not been tabulated here).
Counts of cachets or tablets
Although counts of stocks of cachets or tablets
are a valuable means of checking on the co-operation
of individual patients, the findings are not suitable
for purposes of analyses (for reasons, see Tuber-
culosis Chemotherapy Centre, Madras, 1960) and
are therefore not presented here.
TH
patientsPercentage of occasions on which patients
PH
attended on the appointed day
patients
of the week or earlier b No. %
90 or more 44 65 36 49
80-89 9 13 19 25
70-79 8 12 8 11
60-69 4 6 8 11
50-59 3 4 2 3
Less than 50 0 0 1 1
Total 68 100
Patients who became uncooperative and
(a) received no treatment for more
than six weeks 2 –
(b) refused further treatment 1 –
All patients 71c         –
P6H/H
patients
No. %  No. %
           41 63
1 1 17
6 9
5 8
2 3
0 0
73 100 65 100
2  – 4  –
2  – 2  –
77      – 71                 –
TABLE 15
REGULARITY OF WEEKLY ATTENDANCE FOR COLLECTION OF DRUGS
DURING THE YEAR OF TREATMENT=
a The policy for including In the analyses patients who did not receive the allocated chemo-
therapy throughout the 12-month period Is described on page 489.
b Excluding periods during which patient was In hospital or sanatorium or under desensitiza-
tion.
c Excluding one patient who died In the first month.
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CO-OPERATION OF PATIENTS
There were 13 patients (3 PH, 4 TH, 6 P6 /H) who
became very uncooperative, including 5 (1 PH,
2 TH, 2 P6H/H) who refused further treatment.
Table 15 sets out the regularity with which the
remaining 68 PH, 73 TH, and 65 P6H/H patients
(excluding 1 PH patient who died in the first month)
attended on the appointed day of the week (or
earlier).Regularity on 90% or more of the occasions
was observed in 65 % of the PH, 49 % of the TH and
63% of the P6H/H patients; the proportions who
were regular on less than 70% of the occasions were
10%, 15 % and 11 %, respectively. Thus, the PH and
the P6H/H series had very similar distributions for
regularity of attendance. There was some evidence
that the TH patients were, on the average, less regular
in attending the clinic to collect their drugs; indeed,
the difference between this series and the PH series is
statistically significant (P = 0.03).
An analysis (not tabulated here) was undertaken
to study whether the regularity of attendance was
affected by the passage of time. In the PH series, the
pr portion who attended on the appointed day (or
arlier) on all occasions was 60 % in the first quarter,
42 % in the second, 38 % in the third and 42 % in the
fourth quarter. The corresponding proportions
ere 45 %, 37 %, 24 % and 18 % in the TH series and
51%, 34 %, 42 % and 37 % in the P6H/H series.Thus,
in all three series, the patients attended less regularly
in the later nine months of treatment, there being a
noticeably strong trend in the proportions for the
four quarters in the TH series.
IX. PATIENTS NOT INCLUDED IN THE MAIN ANALYSIS
This section describes the progress during treat-
ment of 20 patients (7 PH, 3 TH, 10 P6H/H) who
were excluded from the main analysis, 17 because
they had had isoniazid-resistant strains of tubercle
bacilli at the start of treatment, one because his
pretreatment sensitivity test results were anomalous
and two because they had anonymous mycobacterial
infections. All continued on the allocated regimen.
PATIENTS WITH ISONIAZID-RESISTANT ORGANISMS
AT THE START OF TREATMENT
The 17 patients with isoniazid-resistant strains of
tubercle bacilli on admission were interrogated again
during the course of treatment, as their relation with
the Centre’s staff became established, to discover
whether they had concealed a history of previous
chemotherapy. Two (1 PH, 1 TH) admitted to
previous treatment with isoniazid for approximately
three weeks and two months, respectively; they are
regarded as having acquired resistance from previous
chemotherapy. It is presumed that the remaining
15 patients (5 PH, 1 TH, 9 P6H/H), with no history
of previous chemotherapy, had been infected with
isoniazid-resistant organisms-that is, had primary
isoniazid resistance (an incidence of 6.4 %).
The detailed results of isoniazid-sensitivity tests on
two pretreatment cultures and the response to
treatment are set out for all 17 patients in Table 16.
Both the patients with acquired isoniazid resistance
had an unfavourable response, as did 12 of 15
patients with primary isoniazid resistance.
There were 15 patients who, on admission, had
prim ry or acquired isoniazid resistance and who
received isoniazid plus PAS (PH or P6H/H); none
had a history of previous treatment with PAS
although one had received isoniazid. On the basis
of a single pretreatment culture, all (except one who
had no test) were classified as having a PAS-
sensitive infection on admission. At six months, 10
pati ts had positive cultures of which six were
classified as resistant to PAS. Thus, there is clear
evidence that the PAS-sensitivity test, as carried out
in this study, was able to detect the emergence of
esi tance to PAS in patients with isoniazid-resistant
organisms initially.
PATIENTS WITH ANOMALOUS PRETREATMENT
SENSITIVITY TEST RESULTS
One patient (PH) has been excluded from the
analysis because he had one pretreatment culture
resist nt to isoniazid, streptomycin and PAS (MIC
of 50 µg/ml, an RR of 8 and an RR of 4, respectively),
althou h two other pretreatment cultures were
sensitive to all three drugs; a discrepancy of this type
is very unusual at the Centre and suggests that one of
the pretreatment specimens was incorrectly labelled.
PATIENTS WITH ANONYMOUS MYCOBACTERIAL
INFECTIONS
For two patients (1 TH, 1 P6H/H), the cultures
from specimens obtained on admission were pure
growths of photochromogenic organisms;’ these were
1 Subsequently identified as Mycobacterium kansasii.
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TABLE 16
RESPONSE TO TREATMENT IN PATIENTS WITH ISONIAZID-RESISTANT
ORGANISMS ON ADMISSION
lsoniazid
resistance
Acquired
Primary
R72
R9
R193
R198
R143
R58
R78
R153
R128
R171
R203
R94
R236
R67
R91
R221
R127
Treatment
series
PH
TH
PH
PH
PH
PH
PH
TH
P6H/H
P6H/H
P6H/H
P6H/H
P6H/H
P6H/H
P6H/H
P6H/H
P6H/H
MIC a of isoniazid
on 2 cultures on admission
5 5
5 5
50 50
5 5
1, 1 1, 1
1, 1 1, 1
1, 5 0.2
5 0.2
50 5
5 5
5 5
5 > I
1, 1 1, 1
1, 1 1, 1
1, 1 1, 1
1, 1 1, 0.2
1, 1 0.2
Response
to treatment
at 12 months
Unfavourable b
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Favourable c
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Favourable
Favourable
Unfavourable
Unfavourable
Unfavourable
Unfavourable
a Minimal inhibitory concentration.
b Bacteriologically active disease at 12 months including termination of allocated chemo-
therapy owing to persistent sputum positivity or serious radiographic or clinical deterioration.
c Bacteriologically quiescent disease at 12 months.
niacin-negative and highly resistant to isoniazid andha positive cultures at the first month only. All posi-
PAS. The TH patient had positive cultures from 1 totive cultures during treatment from both these patients
6 months and at 8 and 9 months. The P6H/H patient were pure growths of photochromogenic organisms.
X. DISCUSSION
The cost of chemotherapy is a major consideration(Tuberculosis Chemotherapy Centre, Madras,
in planning antituberculosis programmes in many196313); however, it is not as effective as a standard
developing countries and, therefore, studies at thedaily regimen of 200 mg of isoniazid plus 10 g of
Centre continue to be directed towards findingsodium PAS, given in two divided doses (Tuber-
regimens which are inexpensive, effective, non-toxicculosis Chemotherapy Centre, Madras, 1960)—the
and acceptable to the patients, and hence suitable forPH regimen of the present study. The present study
application on a wide scale. Isoniazid alone, givenwas designed to compare for a year two dual-drug
in its optimal dosage of approximately 8-9 mg/kgoral re imens, less expensive and smaller in bulk, with
body-weight as a single daily dose, is inexpensivethe standard PH regimen. One of these was the TH
and, if given with 6 mg of pyridoxine, non-toxicregimen, that is, 300 mg of isoniazid plus 150 mg of
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thioacetazone given in one dose daily for the whole
year. This regimen has been found to be as effective
as the PH regimen in East African patients (East
African/British Medical Research Council Second
Thiacetazone Investigation, 1963). The other was
a 2-phase regimen of 200 mg of isoniazid plus 6 g of
sodium PAS given daily in one dose for the first 6
months, followed for the second 6 months by
isoniazid alone in one daily dose of 300 mg–the
P6H/H regimen.
THERAPEUTIC EFFICACY
The therapeutic efficacies of the PH and TH
regimens were the same, 82 % of the patients in each
series having a favourable response to treatment, and
this confirms the findings in East Africa (East
African/British Medical Research Council Second
Thiacetazone Investigation, 1963). The P6H/H
patients, however, fared less well, only 67 % having a
favourable response.
The PH regimen
The efficacy of the PH regimen in this study was of
the same order as in three previous studies by the
Centre (Tuberculosis Chemotherapy Centre, Madras,
1959, 1960, 1964), in which 86%, 91% and 85% of
the patients had a favourable response (average of
87 %), and was within the expected range (95 % con-
fidence limits) of 79 % to 95 %. The severity of the
disease on admission was broadly similar in the four
studies.
The TH regimen
The therapeutic results with thioacetazone plus
isoniazid in the present study are encouraging.
Favourable results with this combination have also
been reported from other parts of India (Deshmukh,
Master & Kulkarni, 1963; Sikand, Goyal & Mathur,
1964; Menon, 1965).
It is of interest to compare the findings in the
present study with those in East Africa. Mitchison
& Lloyd (1964) have reported, on the basis of a
concurrent comparison, that cultures of tubercle
bacilli from previously untreated patients are more
often resistant to thioacetazone in Madras than in
East Africa. In a further unpublished concurrent
comparison, an MIC of 2 µg/ml has been found in
83 % of patients at Madras and in 39 % of patients in
East Africa (Mitchison, personal communication,
1966). (Supporting evidence from the present study
that Madras strains are more often resistant before
treatment is derived from the fact that resistance
merg d during treatment less frequently in Madras
than n East African patients.) Further, an associa-
tion between pretreatment thioacetazone sensitivity
and unfavourable response to treatment was found
in East Africa in patients receiving isoniazid plus
thioacetazone; it might therefore be expected that
the TH regimen in Madras would be less effective.
However, thioacetazone-resistant strains from un-
treated Madras patients are frequently of low
virulence (Joseph et al., 1964), and it has been shown
by Ramakrishnan et al. (1961) that Madras patients
with strains of low virulence progress slightly more
satisfactorily when treated with isoniazid alone than
patients with strains of high virulence. Thus, the
therapeutic disadvantage of pretreatment thioaceta-
zone-resistant strains may be offset to some extent by
the possible advantage gained from their low
virulence.
The P6H/H regimen
Bowerman (1957) has reported a controlled
comparison in which a daily dosage of 10-12 g of
PAS, given in divided doses, was slightly more
effective in combination with isoniazid than was
5-6 g also given in divided doses. However, there is
subsequent evidence that a singlehigh dose of PAS
can saturate the acetylating process of the body more
effectively than a series of small doses and thus
result in higher concentrations of therapeutically
active PAS in the blood (Lehmann, 1959; Wagner,
Fajkosova & Simane, 1960; Bang et al., 1962). In
the present study, the proportion of patients with a
favourable response at six months was 81% for the
PH and 76% for the P6H/H series. There was
therefore only a suggestion that at six months the
PH patients had responded better bacteriologically.
Reisner & Shaw (1963) and Reisner (1964, 1965)
reported on a controlled study comparing (a) a
regimen of 300 mg of isoniazid plus 6 g of PAS
(equivalent to 8.3 g of sodium PAS) given in one
dose daily with (6) a regimen of 300 mg of isoniazid
n ne dose plus 12 g of PAS in three divided doses
and ( ) a regimen of 300 mg of isoniazid plus 12 g of
PAS, both drugs being given in three divided doses.
T ey found at four months that the regimen con-
taini g 6 g of PAS was as effective as the other two
regimens in all respects.
The proportions of patients with an unfavourable
response to treatment in the P6H/H series increased
from 24 % at six months to 33 % at one year, whereas
the c rresponding proportions for the PH series
were 19 % and 18 %, respectively. It has been
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observed in the Centre that when any regimen,
irrespective of its therapeutic effectiveness, is given
for a year, the results at one year closely resemble
those at six months, a finding that was observed in
the PH series (and also the TH series) in the present
study. It is therefore likely that the same would have
applied to the regimen containing 200 mg of iso-
niazid plus 6 g of PAS had it been continued for the
full year. If this is so, it follows that isoniazid alone
in the second six months was unable to maintain
the progress attained by patients in this series at the
end of the first six months. However, the efficacy of
maintenance chemotherapy with isoniazid alone may
well depend on the intensity of the initial treatment
as, in the International Union against Tuberculosis
Investigation (1964), it was found that in patients
who had had 28 weeks of triple- drug chemotherapy
(streptomycin, isoniazid and PAS), all of 33 who were
allocated at random to isoniazid alone had all
cultures negative at 52 weeks (and 35 of 37 patients
who were allocated isoniazid plus PAS).
TOXICITY
Severe toxic reactions, requiring an interruption or
termination of chemotherapy, occurred to similar
extents in the PH and TH series, but were rather less
frequent in the P6H/H series, the proportions being
11% of 71 PH, 12% of 75 TH and 4% of 71 P6H/H
patients.
Cutaneous hypersensitivity was the commonest
serious reaction and occurred in 4 PH, 5 TH and
1 P6H/H patients, all of whom were affected in the
first 3 months, 3 of them (all TH) in the first month.
Hypersensitivity due to PAS was less common
in patients receiving the 6-g dosage than in those
on the 10-g dosage, in keeping with the report of
Bowerman (1957).Although the incidence of
cutaneous hypersensitivity in the PH and the TH
series was similar, the reactions were more severe in
the TH patients, two of whom required urgent
hospital admission,one for a Stevens-Johnson
syndrome and the other for a Stevens-Johnson
syndrome and extensive exfoliative dermatitis; two
other patients had early exfoliative dermatitis. Other
cases of exfoliative dermatitis due to thioacetazone
have recently been reported in India and elsewhere
(Raj Narain, personal communication, 1963; Meh-
rotra et al.,1965; East African/British Medical
Research Council Third Thiacetazone Investigation,
1966); it is therefore important that clinicians
giving thioacetazone should exercise particular
caution when skin hypersensitivity occurs.
Thioacetazone, when administered in a daily
dosag  of 200 mg or more, has been reported to be
particularly toxic to the liver and haemopoietic
system (Hinshaw & McDermott, 1950; Bunn, 1950).
In the present study, in which it was given in a single
daily dose of 150 mg, there was no evidence of a
greater incidence of serious liver toxicity than with
s dium PAS in a dosage of 10 g daily, since jaundice.
(not necessarily due to drug toxicity) occurred in
two PH and two TH patients. Also, at the end of
the year of treatment, there was a similar rise in the
serum GOT level in patients receiving TH and
P6H/H (no estimations were undertaken for patients
receivi g PH). It is possible that this rise was due to
an improvement in the nutritional state of the
patients as Babcock, Brush & Sostman (1960) have
reported a rise in the average serum GOT levels
after the administration of vitamin B6 to 15 college
students who had been deprived of this vitamin in
their diets.
Considering the toxic effect on the haemopoietic
system, the average total leucocyte and polymorpho-
nuclear cell counts fell to a similar extent during
the year in all three series. A neutropenia of less
than 1000 cells/mm3 was observed in only one TH
patient and might have been due to thioacetazone.
However, the average haemoglobin level rose only
by 0.9 g per 100 ml over 12 months in the TH series,
as compared with 1.6 g per 100 ml in the PH series
and 2.1 g per 100 ml in the P6H/H series; the corres-
ponding increases in the PCV values were 2.5%,
4.1% and 4.7%, respectively; all the increases are
statistically significant. These findings are similar to
those reported from East Africa (East African/
Bri ish Medical Research Council Thiacetazone/
Diphenylthiourea Investigation, 1960).
Gastrointestinal disturbances due to thioacetazone
have been reported to occur commonly (Deshmukh
& Master, 1962). In the present study, two patients
in each of the three series had severe gastrointestinal
complaints necessitating an interruption of chemo-
t erapy. Minor complaints of anorexia, vomiting
and giddiness, not requiring any interruption of
chemotherapy, were recorded much more frequently
among the TH patients. However, since isoniazid
plus thioacetazone was being used for the first time
in the Centre, it is possible that the clinicians were
more assiduous in recording complaints from
p e ts treated with this regimen. (Nevertheless, it
is of interest that the TH patients gained, on the
average, only 6.0 lb during the year, as compared
with 10.6 lb for the PH and 10.3 lb for the P6H/H
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patients; the differences being highly significant
(P<0.01).) Glycosuria occurred in 31% of 65 TH
patients, as compared with 13 % of a control group
of 61 P6H/H patients (P=0.03); it was, however, not
a persisting feature as the testresults were negative
in all but one patient aftercessation of chemo-
therapy. Three patients were investigated further
and found to have a normal glucose tolerance
curve. However, Haynes (1952) has reported two
East African patients who, on each occasion thio-
acetazone was administered, developed episodes of
glycosuria with a diabetic-type glucose tolerance
result. Escovitz (1952) has also reported two
patients with pulmonary tuberculosis who showed
demonstrable impairment of carbohydrate meta-
bolism associated with prolonged administration of
Amithiozone (thioacetazone) and Mitra (1964) has
noted glycosuria and hyperglycaemia in 3 of 50
patients treated with Tebafen (nicotinaldehyde thio-
semicarbazone+isonicotinic acid hydrazide).
The frequency of minor side-effects in the TH
regimen might prove to be important in that the
acceptability of the regimen might be adversely
affected. There is some evidence in the present
study that patients in the TH series were less regular
in attending the clinic to collect their weekly supply
of drugs, as compared with patients in the PH and
the P6H/H series. It has been claimed (Deshmukh
& Master, 1962) that vitamins and antihistamine
additives reduce the incidence of side-effects, and
this is to be the subject of an investigation by the
Medical Research Council of Great Britain in a
number of countries, including India. It is also
possible that a reduction in the incidence might be
achieved by giving the thioacetazone in two doses
daily, without necessarily impairing the therapeutic
effect (Sikand, Goyal & Mathur, 1964).
BACTERIAL RESISTANCE TO THE DRUGS
In previous studies in the Centre, the PAS-
sensitivity test, using an undiluted inoculum, was not
found to be satisfactory for classifying strains as
sensitive or resistant (Tuberculosis Chemotherapy
Centre, Madras, 1959, 1960). In the present study, a
smaller inoculum (obtained from a 1 in 10 dilution)
was therefore used (for reasons, see Selkon et al.,
1960), and although there was some improvement
the test was still not very satisfactory. Thus, in
patients with isoniazid-sensitive organisms on ad-
mission, the sensitivity to PAS of the pretreatment
cultures did not appear to influence the response
to treatment either in the PH or in the P6H/H series.
However, there was evidence that the test measures
acquired resistance, but that resistance emerged
infreq ently during treatment with isoniazid plus
PAS. The occurrence of PAS-sensitive strains during
treatment is presumably because PAS, as has been
shown in vitro, may not inhibit but only delay
the growth of PAS-sensitive organisms (Singh,
1954; Mitchison, 1965). On the other hand, there is
vidence from both the present study and the East
African studies (East African/British Medical
Res arch Council Pretreatment Drug Resistance
Report, 1963) that in patients with initially isoniazid-
resistant organisms who are treated with isoniazid
plus PAS (and in whom PAS may therefore be acting
alon ), PAS resistance emerged more frequently;
there is also some evidence that PAS resistance
emerges in patients treated with PAS alone (Great
Britain, Medical Research Council, 1950).
Finally, there is some evidence in the present
study that the emergence of isoniazid resistance
occurred earlier in the TH series than in either of the
two isoniazid plus PAS series, although it should be
noted that in the later months of treatment the
opor ion of patients with isoniazid-resistant
organisms in the TH and PH series were similar.
The explanation for this may be that PAS may delay
the growth of isoniazid-resistant mutants in the same
anner as it delays the growth of isoniazid-sensitive
organisms in vitro (see above).
CONCLUSION
This study has shown that isoniazid in a dosage of
300 mg plus thioacetazone in a dosage of 150 mg
given together in one dose daily is as effective as the
standard regimen of isoniazid plus PAS. However,
there is conflicting evidence on the incidence of
thioacetazone toxicity and, further, there is evidence
of geographical variations in the prevalence of
naturally occurring thioacetazone-resistant strains of
tubercle bacilli (Mitchison & Lloyd, 1964); these
sugge t that it would be advisable to establish the
oxicity and therapeutic efficacy of thioacetazone
under local conditions by conducting careful pre-
liminary trials before introducing it on a large scale
in any country (see also World Health Organization
Expert Committee on Tuberculosis, 1964). Finally,
there is also some suggestion that 200 mg of isoniazid
plus 6 g of PAS, given in one dose daily for one year,
might prove as effective as 200 mg of isoniazid plus
10 g of PAS, given daily in two divided doses for
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XI. SUMMARY
1. Two hundred and forty South Indian patients
with advanced pulmonary tuberculosis were allo-
cated at random to treatment for one year with one
of three regimens of daily, oral, chemotherapy; the
patients were treated on an out-patient basis and
required to administer the drugs themselves at home.
2. The three regimens and the daily dosages for a
patient weighing 100 lb (45.4 kg) were:
PH: Isoniazid 200 mg plus sodium PAS 10 g, in
two divided doses
TH: Isoniazid 300 mg plus thioacetazone 150
mg, in one dose
P6H/H: Isoniazid 200 mg plus sodium PAS 6 g, in
one dose for the first 6 months, followed by
isoniazid 300 mg in one dose for the
second 6 months.
3. The main analysis of this report concerns 220
of the 240 patients-namely, the 72 PH, 77 TH and
71 P6H/H patients who had organisms sensitive to
isoniazid on admission; of these, 214 had received no
previous chemotherapy while the remaining 6 had
received it for not more than 2 weeks.
4. The clinical, radiographic and bacteriological
condition of the patients in the three series were
similar at the time of admission.
5. During the year there were 8 deaths, 2 (1 PH,
1 TH) from tuberculosis, and 6 (2 PH, 4 TH) from
non-tuberculous causes; serious clinical or radio-
graphic deterioration necessitating termination of
the allocated chemotherapy occurred in 3 PH, 3 TH
and 7 P6H/H patients.
6. At one year, 82 % of 66 PH, 82 % of 65 TH and
67% of 63 P6H/H patients were classified as having
a favourable response, mainly on the basis of culture
results at 10, 11 and 12 months.
7. The majority of patients showed at least
moderate radiographic improvement over the year–
namely, 83 % of the PH, 77 % of the TH and 70 % of
the P6H/H patients. Cavitation disappeared in 70%
of 44 PH, 69% of 39 TH and 61% of 41 P6H/H
pa ients with initial cavitation and became less in
7 %, 18 % and 15 %, respectively.
8. Chemotherapy was interrupted or terminated
on account of toxicity in 8 (11%) PH, 9 (12 %) TH
and 3 (4%) P6H/H patients; this was due to cuta-
neous hypersensitivity in 4, 5 and 1, jaundice in 2, 2
and 0, and severe gastrointestinal complaints in 2, 2
and 2, respectively. Exfoliative dermatitis was
observed in 3 patients (all TH).
9. Complaints of vomiting were recorded in 8%
of the PH, 23 % of the TH and 15 % of the P6H/H
patients, of anorexia in 7 %, 17 % and 4% respec-
tively, and of giddiness in 4%, 28% and 10%,
respectively. Glycosuria during treatment occurred
in 31% of the TH patients, as compared with 13 % of
the P6H/H patients. Neurological complications due
to isoniazid occurred in 1 TH and 1 P6H/H patient.
10. The average haemoglobin value in the PH
series increased from 11.7 g per 100 ml on admission
to treatment to 13.3 g per 100 ml at 12 months; the
corresponding figures were 11.5 and 12.4 g in the TH
series, and 10.9 and 13.0 g in the P6H/H series.
11. Major non-cooperation was encountered in
13 patients (3 PH, 4 TH, 6 P6H/H) including 5 (1 PH,
2 TH, 2 P6H/H) who refused further treatment. In
all three series, patients attended the Centre less
regularly to collect their drugs in the later months of
treatment.
12. This study has shown that the regimen of
isoniazid plus thioacetazone (TH) was as effective as
the standard regimen of isoniazid plus PAS (PH) in
the treatment for one year of patients with advanced
pulmonary tuberculosis. However, the thioacetazone
regimen had a higher incidence of side-effects. A
2-phased regimen of isoniazid plus 6 g of PAS for
the first 6 months followed by isoniazid alone for
the second 6 months (P6H/H) was less effective.
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Regimen
PH
P6H/H
TH
First
months
Second
months
50-79
80-99
100 or more
50-69 200
70-89 250
90 or more 300
50-79
80-99
100 or more
200
200
200
50-69 200
70-89 250
90-109 300
110 or more 350
APPENDIX TABLE A
DOSAGE OF DRUGS IN RELATION TO BODY-WEIGHT
Total daily dosage
lsoniazid
m g
150
175
200
Sodium PAS (g)
7.50
8.75
10.00
–
–
Thioacetazone
–
–
100 8.8-6.4
125 7.9-6.2
150 7.3 or less
– 8.8-5.6
5.5-4.4
4.4 or less–
–
–
–
Dosage in relation to body-weight
Isoniazid
m
6.6-4.2
4.8-3.9
4.4 or less
8.8-6.4
7.9-6.2
7.3-6.1
7.0 or less
0.33-0.21
0.24-0.20
0.22 or less
–
0.26-0.17
0.16-0.13
0.13 or less
–
–
Thioacetazone
m Morning Evening
–
3
3
4
4.4-3.2 4
3.9-3.1 5
3.7 or less 6
-
No. of cachets or tablets
to be taken daily
3
4
4
0
0
0
0
0
0
0
0
0
0
a 1 lb = 0.45 kg.
APPENDIX TABLE B. SERUM AND BLOOD GOT VALUES ON ADMISSION AND AT 3, 9 AND 12 MONTHS
TH patients P6H/H
At 3 months
No. %
3 4
19 28
30 43
10 14
7 10
69 99
patients
At 9 months
No. %
0 0
13 21
28a 45
13 21
0 13
62 100
24.3 28.9
1 –
7 10
13 19
40 58
9 13
4  –
1 2
4 6
44a 70
14 22
69 100
575
63 100
620
1  –
1  –
0  –
71               –
3  –
1  –
4  –
71                –
. -
-
At 12 monthsOn admission
No. %
3 4
28 39
32 45
6 8
2 3
71 99
21.3
4 –
7 10
8 11
43 61
13 18
71 100
598
4 –
– –
– –
75 –
At 3 months
No. %
5 7
18 25
39 53
7 10
4 5
73 100
22.9
0  –
16 23
13 18
37 52
5 7
71 100
529
2  –
1  –
1  –
75              –
At Q months
No. %
3 5
18 28
30 47
11 17
2 3
64 100
23.2
2 –
3 5
21 33
37 58
3 5
64 101
545
2 –
1 –
8 –
75 –
On admission
No. %
2 3
30 44
26 38
5 7
5 7
68 99
21.8
3 –
3 5
6 9
44 67
13 20
66 101
602
5 –
– –
– –
71 –
At 12 months
No. %
0 0
10 16
27 44
17 27
8 13
No. %
0 0
5 9
30 56
9 17
10 19
54 101
Less than 10
10-
20-
30-
40 or more
Total b
Average
No result available
Less than 400
400-
500-
700 or more
Total b
Average
No result available
62 100
28.2 29.9
4  – 7  –
4 7
10 16
41 67
6 10
2 4
5 9
39 74
7 13
61 100 53 100
600
5  – 8  –
Patients who had their allocated
chemotherapy terminated on account
of toxicity
1  – 1  –
9  –
Patients who had their allocated
chemotherapy terminated owing to
death, serious radiographic or clinical
deterioration, or non-cooperation
8  –
- -
-
71                  –All patients 76            –
a Including one specimen at 8 months.
b The policy for including In the analyses patients who did not receive the allocated chemotherapy throughout the 12-month period is described on page 489.
APPENDIX TABLE C
HAEMOGLOBIN, PACKED CELL VOLUME AND LEUCOCYTE COUNT VALUES ON ADMISSION TO TREATMENT AND AT 3, 9 AND 12 MONTHS
PH patients TH patients P6H/H patients
At 9
months
12.7 12.4
38.5 38.6
8 100
64 100
2  –
1  –
8  – 8  –
On
admission
At 12
months
On At 3
months
No. % No. %
Average 11.7 11.7
Packed cell volume (%):
Less than 30
30-
35-
40-
45 or more
Average 37.4 36.8
Average 9 800 8 100 9 700 9 300
Total b 71 100 62 100 73 100 73 100
No results available 0  – 2  – 2  – 0  –
Patients who had their allocated
chemotherapy terminated on
account of toxicity –  – 1  – –  – 1  –
Patients who had their allocated
chemotherapy terminated
owing to death, serious radio-
graphic or clinical deteriora-
tion, or non-cooperation –  –
71            –
6  –
71           –
–  –
75                   –
1  –
75                 –
At 12
months
At 9 At 12
months months
On At 3
admission months
No. % No. %
I
No. % No. %
13.4 13.010.9 12.2
I
I
40.8 39.935.2 36.4
7 700
65 100 65 100 54 100
I - 7 -
1  – 1  –
69 100 70 100
2  –  o -
–  – 1  –
1  –
1  –
4  –  9  ––  – 0  –
71    –       71      –75         – 75                –  7 1    –     7 1    –All patients
a Including one specimen at 8 months.
b The policy for Including In the analyses patients who did not receive the allocated chemotherapy throughout the 12-month period Is described on page 489.
